Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-106 +/- pembrolizumab in advanced cancers
NCT05320588Phase 2Recruiting
- Sponsor
- BiOneCure Therapeutics Inc.
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bio-106 in solid tumor (advanced stage), sponsored by BiOneCure Therapeutics Inc.. Started Mar 2022; status: recruiting.
02
Drugs
bio-106
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05320588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05320588.